{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/gonorrhoea/prescribing-information/cephalosporins-ceftriaxone-or-cefixime/","result":{"pageContext":{"chapter":{"id":"9c11c59e-3407-52b9-a870-aed88dcd9236","slug":"cephalosporins-ceftriaxone-or-cefixime","fullItemName":"Cephalosporins (ceftriaxone or cefixime)","depth":2,"htmlHeader":"<!-- begin field bafeab55-ee26-4cd8-bb90-a7610081148b --><h2>Cephalosporins (ceftriaxone or cefixime)</h2><!-- end field bafeab55-ee26-4cd8-bb90-a7610081148b -->","summary":"","htmlStringContent":"<!-- begin item e76ca4ca-62f1-4994-b173-a7610081152c --><!-- end item e76ca4ca-62f1-4994-b173-a7610081152c -->","topic":{"id":"8aeba2d1-9f1a-5428-a119-41fa94223706","topicId":"4b4cdbb6-97a0-4b13-a04c-d857b72bcddf","topicName":"Gonorrhoea","slug":"gonorrhoea","lastRevised":"Last revised in November 2020","chapters":[{"id":"803822d1-16b6-5c36-b47d-9a6e8e236c06","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"b8d98590-b989-554f-8ccb-804279dab0d2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4ac6e3b9-f31e-5367-b177-171c1cd87bd7","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"41812e79-dbe3-5991-8344-05de91dff192","slug":"changes","fullItemName":"Changes"},{"id":"bbabf43d-27dd-5795-b02b-9891c7e9e7ca","slug":"update","fullItemName":"Update"}]},{"id":"cd231f06-b527-5de3-a8cb-277fd6f84587","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"858e0da7-8025-510b-ac87-1055c9b510e0","slug":"goals","fullItemName":"Goals"},{"id":"b9efda8e-7814-5479-af6b-1272844f3546","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"874bc02c-2022-584f-bc91-b99489f3ac6c","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"17fcc032-43d9-5c38-b19b-e10bef0648f1","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"1033f77b-d5e5-5700-b7f9-f314bb1daef3","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"11e8f7de-1c3f-5692-a9e4-f2c1645e1023","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f889ee27-2135-5f9e-b131-fb46452febe4","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"55283c6e-a75b-5deb-8827-406245e897ff","slug":"definition","fullItemName":"Definition"},{"id":"cf7e0416-d49c-57de-8063-ebf536922bcc","slug":"prevalence","fullItemName":"Prevalence"},{"id":"6c929d32-5621-5a53-9e9b-63a3e1523e20","slug":"prognosis","fullItemName":"Prognosis"},{"id":"1196a066-1188-5938-b1d3-932dd0ffc403","slug":"complications","fullItemName":"Complications"}]},{"id":"acc7ed62-ebd4-506d-a105-4b05f6f7e38a","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"a9a1ae79-f8a2-59e3-a720-8207d27eee47","slug":"assessment","fullItemName":"Assessment"},{"id":"0ee9cef7-bd86-583b-9d57-f5d8f9a5d6d0","slug":"signs-symptoms-in-a-man","fullItemName":"Signs and symptoms in a man"},{"id":"9b460f20-3213-5956-896f-ccc5156c9d32","slug":"signs-symptoms-in-a-woman","fullItemName":"Signs and symptoms in a woman"},{"id":"e568c796-6f9e-5513-a973-7efca33d5b62","slug":"confirmation-of-diagnosis","fullItemName":"Confirmation of diagnosis"},{"id":"44933641-db44-5935-9459-ea8e78869d57","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"e0f6f6d2-d4a8-5801-b817-0588e8540a04","slug":"possible-sexual-abuse","fullItemName":"Possible sexual abuse"}]},{"id":"d05b0423-47bb-53df-ab5a-8730ca4d3325","fullItemName":"Management","slug":"management","subChapters":[{"id":"171cfead-d784-5eab-b668-c3fe9015a93a","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"98eac615-b29a-5de3-a795-37b42615eb61","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"9c11c59e-3407-52b9-a870-aed88dcd9236","slug":"cephalosporins-ceftriaxone-or-cefixime","fullItemName":"Cephalosporins (ceftriaxone or cefixime)"},{"id":"af56affe-2e43-5ee7-b94a-333ead3b8efa","slug":"quinolones-ciprofloxacin-or-ofloxacin","fullItemName":"Quinolones (ciprofloxacin or ofloxacin)"},{"id":"caa85d19-223f-5ca5-ae12-313a1b2462d1","slug":"azithromycin","fullItemName":"Azithromycin"}]},{"id":"39f7e7ee-870b-55c8-9cd9-55320d487f24","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"05886abb-50fd-51e9-b3c2-e2e99ad9b241","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bdd6db63-13f7-5183-a3a2-63b619818fb3","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0d44a69c-3824-5509-a756-cda3bc1bd50a","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e5526ef2-c93a-595d-a0c1-8068bad91f10","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"0092236d-21ec-5777-85c0-6e95f9962a15","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"8791b380-0e55-5489-987e-5db590030323","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"bc36d12c-c9a8-5970-8b4b-74304413a1f0","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"98eac615-b29a-5de3-a795-37b42615eb61","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"b994a29a-16c6-5a09-a473-e2a6bdc95034","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field c846c534-1bba-423e-b5cf-a77700835363 --><h3>Adverse effects</h3><!-- end field c846c534-1bba-423e-b5cf-a77700835363 -->","summary":"","htmlStringContent":"<!-- begin item ec515348-dbb4-47fd-90b9-a77700835090 --><!-- begin field 469c20ba-5f9f-4664-b006-a77700835363 --><ul><li>Adverse effects of cephalosporins include:<ul><li><strong>Gastrointestinal</strong> — diarrhoea, nausea and vomiting are common, occurring in 1–10% of people taking ceftriaxone.<ul><li>Abdominal pain (rare).</li><li>Antibiotic-associated colitis (very rare).</li><li>Pseudomembranous colitis — caused by infection with <em>Clostridium difficile</em> (less than 0.01% of people). Consider the possibility of this in people who present with diarrhoea after treatment with ceftriaxone or cefixime.</li></ul></li><li><strong>Hypersensitivity reactions </strong>(uncommon)<strong> </strong>— these may include:<ul><li>Maculopapular rash or exanthema, pruritus, urticaria, oedema,<strong> </strong>shivering and anaphylactic or anaphylactoid reactions (for example bronchospasm) or allergic dermatitis. </li><li>Drug rash with eosinophilia and systemic symptoms (DRESS).</li><li>Stevens-Johnson syndrome (very rare).</li></ul></li><li><strong>Central nervous system </strong>(rare) — headache, vertigo or dizziness.</li><li><strong>Blood and lymphatic disorders</strong> (common) — anaemia, haemolytic anaemia, granulocytopenia, leucopenia, neutropenia, thrombocytopenia and eosinophilia.</li></ul></li><li>Other rare adverse effects may include:<ul><li>Pain and discomfort at the injection site for ceftriaxone.</li><li>Hepatitis and/or cholestatic jaundice, or increase in liver enzymes.</li><li>Glycosuria, oliguria, haematuria, or increase in serum creatinine.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">ABPI Medicines Compendium, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">ABPI Medicines Compendium, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">BNF 73, 2017</a>]</p><!-- end field 469c20ba-5f9f-4664-b006-a77700835363 --><!-- end item ec515348-dbb4-47fd-90b9-a77700835090 -->","subChapters":[]},{"id":"bd873dcf-9c36-5132-a583-5543618b4297","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 8db1bf00-7f73-4cbc-bf68-a77700830d11 --><h3>Contraindications and cautions</h3><!-- end field 8db1bf00-7f73-4cbc-bf68-a77700830d11 -->","summary":"","htmlStringContent":"<!-- begin item 2023ce53-0c1e-4b01-bf2c-a7770083042b --><!-- begin field 5fc89948-1ee7-4680-a03e-a77700830d11 --><ul><li><strong>Do not prescribe cephalosporins for people:</strong><ul><li>With known hypersensitivity to any cephalosporins, beta-lactam antibiotics, or penicillin.<ul><li>Note that gastrointestinal adverse effects alone (e.g. nausea, vomiting, or diarrhoea) do <em>not </em>constitute an allergy to penicillin.</li></ul></li><li>About 0.5–6.5% of penicillin-sensitive patients will also be allergic to the cephalosporins.</li></ul></li><li><strong>Prescribe ceftriaxone or cefixime with caution:</strong><ul><li>If a cephalosporin is essential in patients with a history of immediate hypersensitivity to penicillin.</li><li>In people with a history of gastroinintestinal disorders (for example colitis).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">BASHH, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">ABPI Medicines Compendium, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">ABPI Medicines Compendium, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">BNF 73, 2017</a>]</p><!-- end field 5fc89948-1ee7-4680-a03e-a77700830d11 --><!-- end item 2023ce53-0c1e-4b01-bf2c-a7770083042b -->","subChapters":[]},{"id":"80954fea-90f3-567e-ab69-4a73a157ef8f","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 43385e1a-037c-46c2-9f83-a7770083695a --><h3>Drug interactions</h3><!-- end field 43385e1a-037c-46c2-9f83-a7770083695a -->","summary":"","htmlStringContent":"<!-- begin item 750e1cef-2a7e-4537-8b5e-a7770083674c --><!-- begin field 73ad6c25-ea4f-429b-aa42-a7770083695a --><ul><li><strong>Possible drug interactions for cephalosporins include:</strong><ul><li><strong>Warfarin</strong> — cephalosporins may enhance the anticoagulant effect. Monitor the international normalized ratio (INR), and adjust the warfarin dose accordingly.</li><li><strong>Oral hormonal contraception </strong>— additional contraceptive precautions are <em>not</em> required during or after a course of ceftriaxone or cefixime.<ul><li>However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea. </li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">ABPI Medicines Compendium, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">FSRH, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">ABPI Medicines Compendium, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gonorrhoea/references/\">BNF 73, 2017</a>]</p><!-- end field 73ad6c25-ea4f-429b-aa42-a7770083695a --><!-- end item 750e1cef-2a7e-4537-8b5e-a7770083674c -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}